TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma

Inclusion Criteria: * Patients newly diagnosed as HCC according to European Association for Study of the Liver criteria. * BCLC stage B or C * Child-Pugh class score≤8 * ECOG performance status ≤2 * Etiology: Hepatitis B virus(HBV) infection * Written informed consent (approved by the Institutional Review Board \[IRB\]obtained prior to any study specific screening procedures * Patient must be able to comply with the protocol * Age 18-75 years * Haematology:Absolute neutrophil count (ANC) \> 1.5 x 109/L, Platelet count \> 50 x 109/L, Haemoglobin \> 9 g/dL (may be transfused to maintain or exceed this level) Prothrombin time international normalized ratio \< 1.5 * Biochemistry:Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)\< 5 x the upper limit of normal,Total bilirubin \< 3 x the upper limit of normal,Serum creatinine \< 1.5 x the upper limit of normal,Cholinesterase\>0.5x the lower limit of normal，Prealbumin\>0.5x the lower limit of normal. * Life expectancy of \> 3 months Exclusion Criteria: * BCLC stage D * Child-Pugh Score≥9 * Clinically severe gastrointestinal bleeding within 4 weeks of the start of treatment * Preexisting or history of hepatic encephalopathy * uncontrolled hypertension * Pregnancy (positive serum pregnancy test) or lactation * Serious, non-healing wound, ulcer, or bone fracture * Currently or recent (within the 30 days prior to starting study treatment) treatment of another investigational drug or participation in another investigational study * Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents ( ≤ 6 months prior to study entry), myocardial infarction ( ≤ 6 months prior to study entry), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication * Evidence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of Sorafenib/TACE or patient at high risk from treatment complications * Other severe concomitant disease that may reduce life expectancy * Risk of allergic reactions to the study drugs * Drug abuse or other physical, psychological , or social problems that may interfere with the participation in the study or evaluation of study results